Anti-Human VEGF-Bevacizumab [Clone A4.6.1]
Anti-Human VEGF-Bevacizumab [Clone A4.6.1]
Product No.: LT400
Product No.LT400 Clone A4.6.1 Target VEGF Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Vascular Endothelial Growth Factor; VEGF-A; VEGFA; Vascular Permeability Factor; VPF Isotype Human IgG1κ Applications B , ELISA , FC , IP , N , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Recombinant human VEGF. Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping 2-8°C Wet Ice RRIDAB_2893954 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. WB ELISA Additional Applications Reported In Literature ? B N IP Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165). This product is for research use only. Background Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects. Antigen Distribution VEGF is widely expressed in the thyroid, prostate, and various other tissues. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. In the context of pharmacokinetic (PK) bridging ELISA for measuring drug concentration in serum samples, research-grade VEGF-Bevacizumab biosimilars are used as calibration standards or reference controls through a highly specific and sensitive analytical process. Here's how they are utilized: Role of Biosimilars in ELISA
ELISA Methodology for PK Analysis
Importance of Biosimilars as Reference Controls
In summary, research-grade VEGF-Bevacizumab biosimilars play a critical role in PK bridging ELISA by serving as calibration standards and reference controls, enabling the precise measurement of drug concentrations in serum samples. This process ensures the accuracy and reliability of the pharmacokinetic data obtained from these assays. The primary in vivo models used to administer a research-grade anti-VEGF antibody and study tumor growth inhibition with analysis of tumor-infiltrating lymphocytes (TILs) are syngeneic mouse models and, for human-specific antibodies, humanized or transgenic mouse models. Syngeneic models are favored for detailed TIL characterization due to their intact murine immune systems, while humanized models enable study of human immune responses when investigating human-specific therapeutics. Key contexts and supporting details:
Alternative Model: Xenograft
Summary Table: Model Types and Uses for Anti-VEGF Antibody Studies
For robust immunological studies involving TILs and tumor growth inhibition with anti-VEGF antibodies, syngeneic or appropriately engineered murine models are predominantly used, tailored by the species specificity of the antibody and the therapeutic hypothesis. Researchers use the VEGF-Bevacizumab biosimilar in combination with immune checkpoint inhibitors—such as anti-CTLA-4, anti-PD-1, and potentially anti-LAG-3 antibodies—to study synergistic anti-tumor effects in advanced preclinical and clinical immune-oncology models. These combinations are designed to exploit the complementary mechanisms of angiogenesis inhibition (by blocking VEGF) and immune modulation (by checkpoint blockade), with the goal of enhancing durable anti-tumor immune responses beyond what either approach achieves alone. Synergistic Mechanisms Studied
Combining these therapies leverages both altered vascular context and direct T-cell activation:
Representative Experimental Approaches
Extension to Other Checkpoints (anti-LAG-3, etc.)While published clinical and translational data primarily describe combinations of Bevacizumab with anti-CTLA-4 or anti-PD-1/PD-L1 antibodies, the same research framework is being extended to new checkpoint inhibitors (e.g., anti-LAG-3 biosimilars). Researchers hypothesize similar immunomodulatory and synergistic benefits when combining VEGF pathway inhibition with agents targeting novel immune checkpoints, although explicit published studies with anti-LAG-3 plus bevacizumab biosimilar are limited as of now. Biosimilars in Combination
In summary:Researchers study the synergy between Bevacizumab biosimilars and checkpoint inhibitors by combining their complementary effects—disrupting tumor angiogenesis and reversing immune suppression—then measuring enhanced immune cell responses and improved anti-tumor activity in preclinical and clinical models, generating early evidence for superior outcomes over monotherapy. In immunogenicity testing for anti-drug antibodies (ADAs) against bevacizumab biosimilars, the biosimilar (VEGF-bevacizumab) is typically used as both the capture and detection reagent in a bridging ELISA format to assess the patient's immune response to the therapeutic antibody. Context and details:
Application to VEGF-bevacizumab and ADA testing:
Key technical considerations:
Summary Table: Use of Biosimilar as Reagent in Bridging ADA ELISA
References:
Alternative approaches:
Conclusion: References & Citations1. Pazdur, R. et al. (2018) Clin Cancer Res. 24(18):4365-70. Technical ProtocolsCertificate of Analysis |
Formats Available
